[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"clinical-trials\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:clinical-trials":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,55,94,122,155,188],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100648842","tissue-preservation-in-immediate-1c-implants-using-an-anatomical-prefabricated-healing-abutment-100648842",false,"NCT07727980","Tissue Preservation in Immediate 1C Implants Using an Anatomical Prefabricated Healing Abutment","Aharct","Inclusion Criteria:\n\n* Willing to sign an IRB-approved informed consent and HIPAA authorization form prior to participation.\n* Between the ages of 20 and 75 years old.\n* ASA Classification I and II.\n* Hopeless maxillary or mandibular posterior teeth, eligible for immediate implantation, and with intact\u002Fsuccessfully restored adjacent teeth.\n* Willing to perform tasks associated with the study and to attend all study visits.\n\nExclusion Criteria:\n\n* HbA1c \\>6.5%) as per a chairside test (Siemens Bayer DCA 2000+);\n* smoker (any status);\n* immunodeficiency;\n* history of head and neck radiotherapy;\n* intake of bone anti-resorptive drugs;\n* cysts or tumors in the area;\n* self-reported pregnancy;\n* poor oral hygiene;\n* active periodontal disease;\n* acute endodontic infection and pus discharge on the site itself and adjacent areas;\n* lack of mutually protected occlusion;\n* insufficient inter-occlusal clearance (\\\u003C15 mm);\n* sites with an existing midfacial mucogingival recession\u002Fdeficiency (scar tissue);\n* sites with a high-scalloped, thin biotype.\n\nThose who appear to qualify will have a CBCT scan taken with an open bite and proper retractions of the cheek, lips, and tongue (standard of care), and the following inclusion criteria, based on the CBCT results, must be present in order for the subject to be fully enrolled in the study:\n\n* Sites with an intact or minimally damaged facial bone plate measuring greater than 1 mm in thickness;\n* Sites with at least 5 mm of healthy bone between the socket apex and the relevant anatomical structure (e.g., the maxillary sinus floor in the maxilla or the inferior alveolar nerve, submandibular\u002Fsublingual fossa, mental foramen, or anterior loop of the inferior alveolar nerve in the mandible);\n* In multirooted molar sockets, the presence of a short root trunk and an interradicular septum with a minimum height of 5 mm and a thickness of 3 mm.","ALL","20 Years","75 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate whether an anatomical prefabricated healing abutment (AHA) improves tissue preservation and clinical outcomes following immediate implant placement after tooth extraction in adults. Although immediate implant placement is a well-established treatment for replacing missing teeth, healing can result in changes to the surrounding bone and soft tissues that may affect the esthetic appearance, function, and long-term stability of the implant-supported restoration. This study will compare an anatomical healing abutment, designed to mimic the natural tooth emergence profile and support peri-implant tissues during healing, with a conventional healing abutment. The primary objectives are to determine whether the AHA better preserves soft tissue contours and alveolar bone, improves implant positioning accuracy and tissue stability during healing, and differs from a conventional healing abutment in complications or adverse events. Eligible participants will be adults requiring extraction of a hopeless tooth in the posterior maxilla or mandible who are suitable candidates for immediate implant placement. Following tooth extraction and implant placement, participants will receive either an anatomical prefabricated healing abutment or a conventional healing abutment and will return for scheduled follow-up visits over approximately 12 months to assess healing, implant stability, and changes in the surrounding hard and soft tissues. Researchers will collect clinical measurements, digital intraoral scans, photographs, and radiographic images throughout the study. Additional research imaging will be used to generate three-dimensional models to measure tissue volume changes and implant position accuracy. Specialized software will compare changes between the two groups over time. Safety will be evaluated by monitoring participants for complications, discomfort, inflammation, implant-related problems, and other adverse events throughout follow-up. All procedures will be performed by trained dental professionals using established clinical protocols. The results may improve understanding of how healing abutment design influences tissue preservation after immediate implant placement and help optimize future implant therapy by supporting better functional, esthetic, and long-term outcomes.",[27,28,29,30,31,32,33,34],"Tooth Loss","Dental Implant","Clinical Trials","Randomized Controlled Trial","Immediate Dental Implant Placement","Molar Extraction Socket","Maxilla","MANDIBLE",[36,37,38,39,40,41],"3-dimensional imaging","wound healing","healing abutments","immediate implant placement","soft tissue dimensional alterations","implant position accuracy","NOT_YET_RECRUITING","2026-07-24",{"date":45,"type":46},"2026-07-27","ACTUAL",{"date":48,"type":21},"2026-09",{"date":50,"type":21},"2028-09",{"name":52,"class":53},"University of Illinois at Chicago","OTHER",2,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":68,"conditions":69,"keywords":76,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":93},"100591115","phase-1-safety-and-early-efficacy-of-ipsc-derived-motor-neuron-progenitor-cells-xs228-in-subacute-spinal-cord-injury-a-phase-i-trial-100591115","NCT06976229","Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial","A Phase I Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Human Allogeneic Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells (XS228 Cell Injection) in Patients With Subacute Spinal Cord Injury","Inclusion Criteria:\n\nAge: 18 to 65 years (inclusive), regardless of gender.\n\nEtiology: Cervical (C4) to lumbar (L2) spinal cord injury (SCI) caused by traumatic injury or surgery-related factors.\n\nSeverity:\n\nClassified as ASIA Impairment Scale (AIS) Grades A, B, or C. MRI-confirmed evidence of spinal cord injury.\n\nDisease Stage:\n\nPrimary SCI occurring 14 to 60 days prior to screening (subacute phase).\n\nContraception:\n\nParticipants of childbearing potential (male and female) must agree to use effective non-hormonal contraceptive methods during the trial and for 6 months after trial completion.\n\nCompliance:\n\nVoluntarily participate in the clinical study. Ability to understand and comply with study procedures. Participant or legal guardian can provide written informed consent.\n\nExclusion Criteria:\n\n* Neurological Inability\n\nPrimary spinal cord injury (SCI) during screening with concomitant severe traumatic brain injury precluding neurological function assessment.\n\nRespiratory\u002FCirculatory Instability\n\nHigh cervical SCI (C1-C3) causing respiratory\u002Fcirculatory compromise requiring endotracheal intubation or tracheostomy.\n\nLife-Threatening Multiorgan Dysfunction\n\nConcurrent severe injuries to other organ systems with life-threatening dysfunction.\n\nUnstable Thoracoabdominal Injuries\n\nInjuries to lungs, liver, kidneys, spleen, etc., deemed unstable by the investigator.\n\nPrior Spinal Pathology\n\nHistory of SCI or coexisting spinal disorders (e.g., ankylosing spondylitis, spinal deformities, primary\u002Fmetastatic spinal tumors, spinal vascular malformations, syringomyelia).\n\nLocal Infection\u002FIncreased ICP\n\nActive infection at the lumbar puncture site or intracranial hypertension during screening.\n\nSevere Infections\n\nSepsis, septic shock, or severe pneumonia (per IDSA\u002FATS 2007 diagnostic criteria).\n\nConfounding Neurological\u002FPsychiatric Conditions\n\nParkinson's disease, severe dementia, myasthenia gravis, stroke, Guillain-Barré syndrome, diabetic neuropathy, or other conditions interfering with study assessments.\n\nCardiac Abnormalities (any of the following):\n\nCongestive heart failure (NYHA Class III\u002FIV). Severe uncontrolled arrhythmias (e.g., sick sinus syndrome, third-degree AV block).\n\nUnstable angina or acute myocardial infarction within 3 months prior. Pulmonary Complications\n\nPulmonary hypertension, pulmonary embolism, or suspected embolism during screening.\n\nUncontrolled Hypertension\u002FHypotension\n\nSystolic BP \\>160 mmHg or diastolic BP \\>100 mmHg; or systolic BP \\\u003C90 mmHg or diastolic BP \\\u003C60 mmHg.\n\nActive Autoimmune Diseases\n\nRequiring immunosuppressants (e.g., uncontrolled hyperthyroidism, systemic lupus erythematosus).\n\nImmunosuppressant Non-Compliance\n\nUnwillingness or inability to use immunosuppressants per protocol.\n\nLaboratory Abnormalities (any of the following):\n\nALT\u002FAST \\>2×ULN or total bilirubin \\>2×ULN. eGFR \\\u003C60 mL\u002Fmin\u002F1.73m² (CKD-EPI 2021 formula). APTT\u002FPT \\>2.5×ULN (without anticoagulants). Platelets \\\u003C100×10⁹\u002FL or hemoglobin \\\u003C90 g\u002FL. Allergy\n\nHistory of severe allergies or hypersensitivity to trial drug\u002Fexcipients (human albumin, lactated Ringer's solution).\n\nInfectious Diseases\n\nHBsAg+ with HBV DNA \\>1000 IU\u002FmL; HCV-Ab+; HIV-Ab+; or TP-Ab+. Lumbar Puncture Refusal\n\nUnwillingness to undergo intrathecal administration procedures. Pregnancy\u002FLactation\n\nFemales who are pregnant or breastfeeding. Malignancy\n\nActive malignancy or anticancer therapy within 5 years prior. Recent Clinical Trial Participation\n\nEnrollment in another drug trial within 3 months prior. Investigator Discretion\n\nAny condition deemed unsuitable for participation by the investigator.","18 Years","65 Years",{"count":65,"type":21},12,[67],"PHASE1","This Phase I clinical trial is designed to evaluate the safety, tolerability of XS228 ( iPSC-Derived Motor Neuron Progenitor Cells) in patients with Subacute Spinal Cord Injury",[70,71,29,72,73,74,75],"Spinal Cord Injury","Safety","Efficacy","Induced Pluripotent Stem Cells","Human Motor Neuron Progenitor","Transplantation",[77,78,79,80,73,81,75],"spinal cord injury","safety","efficacy","clinical trials","Human motor neuron progenitor","RECRUITING","2025-11-19",{"date":85,"type":46},"2025-11-25",{"date":87,"type":46},"2025-07-02",{"date":89,"type":21},"2028-05-30",{"name":91,"class":92},"XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.","INDUSTRY",1,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100586158","effect-of-the-postoperative-trendelenburg-position-on-chronic-subdural-hematoma-recurrence-100586158","NCT06911736","Effect of the Postoperative Trendelenburg Position on Chronic Subdural Hematoma Recurrence","Effect of the Postoperative Trendelenburg Position on Chronic Subdural Hematoma Recurrence: a Clinical Trial","POTHeR","Inclusion Criteria:\n\n* The study included patients aged 18 years or older who required surgical management of symptomatic CSH confirmed by CT scan and whose informed consent was given by the patient or responsible family member to participate in the study\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Conditions in which the trendelenburg position might not be safe, such as intracranial hypertension without a drain to allow evacuation of the hematoma, cardiovascular instability (severe heart failure, unstable angina, cardiogenic pulmonary edema), acute respiratory distress syndrome without a secure airway, glaucoma, spinal cord trauma not stabilized with surgery, peripheral vascular disease,\n* History of ipsilateral chronic subdural hematoma drainage, intracranial hypotension syndrome, ventriculoperitoneal shunting\n* Simultaneous participation in any other clinical trial.",{"count":103,"type":21},254,[24],"Objective: Determine the effect of the postoperative trendelenburg position on the recurrence of chronic subdural hematoma (CSH) in patients undergoing surgery.\n\nMaterials and Methods: An open-label, randomized, controlled clinical trial was conducted in three hospitals in Medellín. Patients with CSH were enrolled and assigned to the trendelenburg position (30° leg elevation and 10° head tilt) or a flat bed for 24 hours postoperatively. CSH recurrence was measured at 3 months, along with functional outcome (modified Rankin scale), adverse events, and comfort (Likert scale).",[107,108,109,110,111,29],"Chronic Subdural Hematoma","Trendelenburg","Recurrence","Mortality","Prognosis","2025-04-16",{"date":114,"type":46},"2025-04-22",{"date":116,"type":46},"2024-06-01",{"date":118,"type":21},"2027-04-30",{"name":120,"class":53},"Universidad de Antioquia",3,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":129,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":140,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100570699","effects-of-cognitive-training-on-chemotherapy-induced-cognitive-impairment-in-colon-cancer-patients-undergoing-treatmentchemobrain-in-oncology-patients-with-colon-cancer-undergoing-active-treatment-100570699","NCT06710639","Effects of Cognitive Training on Chemotherapy-Induced Cognitive Impairment in Colon Cancer Patients Undergoing Treatment(Chemobrain) in Oncology Patients With Colon Cancer Undergoing Active Treatment","Effects of a Cognitive Training Program on Chemotherapy-induced Cognitive Impairment (Chemobrain) in Oncology Patients With Colon Cancer Undergoing Active Treatment: A Randomized Controlled Trial","Inclusion Criteria:\n\nBeing an adult (18 years or older). Having a recent pathological diagnosis of newly diagnosed colon cancer and starting oncological treatment.\n\nBeing fully capable of performing daily functions. Willingness to voluntarily participate in the study and signing the informed consent.\n\nExclusion Criteria:\n\nLack of literacy skills or significant language comprehension deficits. Having a diagnosis of a Central Nervous System tumor or participating in another cognitive stimulation program.\n\nHaving a clinical diagnosis of a neurocognitive disorder as defined in the DSM-V.\n\nWithdrawal Criteria:\n\nDropping out of the program or not completing the final evaluation.",true,{"count":131,"type":21},50,[24],"Introduction: With the increasing survival rate in colon cancer, as a result of technological and biomedical advancements, it is essential to thoroughly study the secondary symptoms related to the oncological disease process. One of the most common and underestimated symptoms is cancer-related cognitive impairment (CRCI).\n\nObjective: To evaluate the efficacy of a cognitive training program in controlling CRCI in individuals with colon cancer undergoing active treatment.\n\nMethodology: A randomized controlled clinical trial with two parallel groups: an intervention group (IG) and a control group (CG). The study population will include individuals newly diagnosed with colon cancer. A sample size of 50 participants has been estimated, with 25 in each group, to detect a difference of 2.95 points or more in the MoCA cognitive impairment questionnaire. All participants will receive an educational leaflet based on the new WHO guidelines, which recommend specific measures to reduce the risk of cognitive impairment. In addition to receiving this informational leaflet, the IG will participate in a cognitive training program (CT) focused on everyday cognition (EC) individually. Each participant will receive a dossier with 80 intervention sessions divided into four training periods (P1-P4), each containing 20 activities. Each period will last for one month. Baseline and 4-month post-intervention evaluations will be conducted for both groups, measuring sociodemographic and clinical variables, as well as study-related cognitive impairment variables: Cognitive function (MoCA test), Everyday Cognition (PECC), Anxiety (Hamilton), Functionality (LB), Sleep Quality (PSQI), Quality of Life (ECOG), and Subjective Memory Complaints (FACT-COG).\n\nImpact: The results of this study could lead to the design of specific cognitive interventions and the establishment of protocols for colon cancer patients undergoing active treatment, helping them manage one of the most underestimated symptoms in this patient population-CRCI-whose incidence is increasing due to the improved survival rates in this disease.",[135,136,137,138,29,139],"Oncology","Cancer-related Cognitive Impairment","Cognitive Training","Everyday Cognition","Colon Cancer",[135,141,142,143,144,145],"Cancer-related cognitive impairment","Cognitive training","Everyday cognition","Clinical trials","Colon cancer","2024-11-26",{"date":148,"type":46},"2024-11-29",{"date":150,"type":21},"2025-03-01",{"date":152,"type":21},"2026-01-31",{"name":154,"class":53},"University of Salamanca",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":162,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":168,"conditions":169,"keywords":173,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":4},"100565366","preconception-folic-acid-clinical-efficacy-preface-trial-100565366","NCT06641245","PREconception Folic Acid Clinical Efficacy (PREFACE) Trial","PREFACE","Inclusion Criteria:\n\n* Non-pregnant females who are:\n* Currently trying to become pregnant;\n* Aged 19-42 years;\n* Low risk for an NTD-affected pregnancy\n\nExclusion Criteria:\n\n* Trying to conceive for ≥6 months (as \\~90% of pregnancies occur after 6 months of trying);\n* Diagnosed ovulatory disorders (polycystic ovary syndrome, endometriosis, or menstrual irregularity);\n* More than 2 miscarriages in the past year;\n* Undergoing fertility assistance (including current IVF or intrauterine insemination);\n* Pre-existing medical condition known to impact maternal folate status (malabsorptive and inflammatory bowel diseases, active celiac disease, gastric bypass surgery, type 1 or 2 diabetes mellitus);\n* Lifestyle factors known to impact maternal folate status (current smoking, \\>6 alcoholic drinks per week, recreational drug use);\n* On the female or male side of those trying to conceive: personal NTD history, previous NTD-affected pregnancy, or personal or family history of other folate sensitive congenital anomalies;\n* Use of folate-inhibiting medications (Chloramphenicol, Methotrexate, Metformin, Sulfasalazine, Phenobarbital, Phenytoin, Primidone, Triamterene, Barbiturates).","FEMALE","19 Years","42 Years",{"count":166,"type":21},272,[24],"A study to help understand what forms of folic acid are most effective to increase folate status during pregnancy for the best protection against neural tube defects",[170,171,29,172],"Folate","Folate Bioavailability","Pregnancy",[174,170,175,176,177,178],"Folic acid","Methylfolate","5-MTHF","RBC Folate","Placental Growth Factor","2024-10-17",{"date":181,"type":46},"2024-10-21",{"date":183,"type":21},"2025-01-31",{"date":185,"type":21},"2030-01-31",{"name":187,"class":53},"University of British Columbia",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":197,"phases":4,"briefSummary":198,"conditions":199,"keywords":203,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":54},"100561246","factors-affecting-selection-of-leadless-pacemaker-and-atrioventricular-synchronous-pacing-status-100561246","NCT06587672","Factors Affecting Selection of Leadless Pacemaker and Atrioventricular Synchronous Pacing Status","Factors Affecting Selection of Leadless Pacemaker in Patients With Atrioventricular Block and Atrioventricular Synchronous Pacing Status With a Micra AV: a Multicenter, Prospective, Observational Study","Inclusion Criteria:\n\n1. Patients diagnosed with atrioventricular conduction block, meeting the indications for dual-chamber leadless pacemakers as per the \"Chinese Expert Consensus on Clinical Application of Leadless Pacemakers (2022)\".\n2. Age ≥18 years.\n3. Expected lifespan ≥1 year.\n4. Consent to sign an informed consent form and cooperate in the collection of baseline data and subsequent follow-ups\n\nExclusion Criteria:\n\n1. Patients anticipated to have a high ventricular pacing proportion (\\>40%) and with left ventricular ejection fraction less than 50%.\n2. Patients with persistent atrial fibrillation and a high expected ventricular pacing proportion.\n3. Post-tricuspid valve mechanical valve replacement surgery.\n4. Patients with inferior vena cava pathway anomalies, precluding passage of the leadless pacemaker's delivery sheath.\n5. Patients with an expected lifespan of less than 1 year. 6 Patients who are pregnant, planning pregnancy, or undergoing cardiac transplantation.",{"count":196,"type":21},112,"OBSERVATIONAL","This is a multicenter, prospective, observational study ,the aim of this study is to find factors affecting selection of double-chamber leadless pacemaker in patients with atrioventricular block and ambulatory atrioventricular synchronous pacing status over time using a leadless ventricular pacemaker.",[200,201,29,202],"Pacemaker","Atrioventricular Block","Pacing",[204,205,206,207],"Leadless pacing","Atrioventricular synchrony","Atrioventricular block","Atrial contraction","2024-09-04",{"date":210,"type":46},"2024-09-19",{"date":212,"type":21},"2024-09-15",{"date":214,"type":21},"2027-07-31",{"name":216,"class":53},"Xiaohan Fan"]